Tumors of the breast in AYAs often lack expression of therapeutic targets, such as estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) oncoprotein (i.e., they are of the triple-negative subtype), and have a poor prognosis [2, 4]. This evidence concerns the gene ERBB2 and breast neoplasm.